Christopher Senner Sells 34,278 Shares of Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) CFO Christopher Senner sold 34,278 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $43.00, for a total value of $1,473,954.00. Following the completion of the sale, the chief financial officer owned 1,042,579 shares of the company’s stock, valued at approximately $44,830,897. This represents a 3.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Exelixis Trading Down 0.7%

Shares of EXEL opened at $44.16 on Friday. The company’s 50 day simple moving average is $43.83 and its 200-day simple moving average is $41.15. The firm has a market cap of $11.47 billion, a PE ratio of 15.94, a price-to-earnings-growth ratio of 1.00 and a beta of 0.42. Exelixis, Inc. has a 12-month low of $32.38 and a 12-month high of $49.62.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.74 by $0.20. The firm had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. Exelixis’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.55 EPS. As a group, equities research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

More Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q4 earnings beat: Exelixis reported $0.94 EPS vs. $0.74 expected and showed y/y revenue growth (Q4 revenue $598.7M), which supports earnings momentum and margin strength. MarketBeat EXEL summary
• Positive Sentiment: Institutional / analyst backdrop is broadly constructive: multiple funds have added or increased stakes and several analysts have maintained or slightly raised targets (consensus target ~ $47.11), which leaves upside if execution/clinical data remain favorable. Analyst & institutional notes
• Neutral Sentiment: Short interest note appears anomalous — the reported February short interest shows 0 shares (short‑interest ratio 0.0 days), likely a data reporting artifact and not informative for positioning. (Source: short‑interest entry)
• Neutral Sentiment: Technical / valuation context: market cap ~ $11.5B, P/E ~16, 50‑day sma ≈ $43.8 and 200‑day sma ≈ $41 — the stock sits between short‑ and long‑term averages so momentum could swing with new catalysts. Key metrics
• Negative Sentiment: Large executive/insider selling this week: EVP Patrick Haley sold 67,814 shares (~$2.95M on Feb 17). Such large insider disposals can create negative optics about timing or liquidity needs. Haley SEC filing
• Negative Sentiment: Repeated CFO sales: Christopher Senner disclosed two sales (34,278 on Feb 13 and 30,617 on Feb 17) totaling roughly $2.8M, which amplifies negative insider‑selling optics. CFO SEC filings
• Negative Sentiment: Director-level reductions: Director Bob Oliver sold 30,250 shares (~$1.33M; ~59% reduction) and other insiders (SVP Brenda Hefti, Director Sue Eckhardt) also sold smaller blocks — combined insider sales this week approximate $8–9M, which likely pressured sentiment. Oliver SEC filing Hefti SEC filing Eckhardt SEC filing

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of EXEL. Police & Firemen s Retirement System of New Jersey lifted its position in Exelixis by 0.3% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 102,581 shares of the biotechnology company’s stock worth $4,521,000 after buying an additional 274 shares in the last quarter. Richardson Financial Services Inc. increased its stake in shares of Exelixis by 95.1% in the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 292 shares during the last quarter. RHS Financial LLC raised its holdings in shares of Exelixis by 2.4% during the fourth quarter. RHS Financial LLC now owns 12,619 shares of the biotechnology company’s stock worth $553,000 after acquiring an additional 293 shares in the last quarter. Meeder Advisory Services Inc. boosted its position in Exelixis by 5.8% during the fourth quarter. Meeder Advisory Services Inc. now owns 5,406 shares of the biotechnology company’s stock valued at $237,000 after purchasing an additional 298 shares during the last quarter. Finally, Cim LLC boosted its position in Exelixis by 0.9% during the third quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock valued at $1,462,000 after purchasing an additional 305 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on EXEL shares. Stifel Nicolaus raised their price target on Exelixis from $43.00 to $44.00 and gave the stock a “hold” rating in a report on Wednesday, February 11th. UBS Group set a $41.00 price objective on Exelixis in a research report on Monday, January 5th. TD Cowen reiterated a “buy” rating on shares of Exelixis in a research note on Wednesday, November 5th. Royal Bank Of Canada boosted their target price on Exelixis from $45.00 to $46.00 and gave the company a “sector perform” rating in a report on Wednesday, February 11th. Finally, Wells Fargo & Company upped their price target on Exelixis from $30.00 to $35.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $47.11.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.